Progression of dual immunotherapy in non-small cell lung cancer
10.3760/cma.j.cn101721-20231113-00137
- VernacularTitle:双重免疫治疗在非小细胞肺癌中的研究进展
- Author:
Yifei XIE
1
;
Cheng CHEN
;
Yuan WEI
;
Jian'an HUANG
Author Information
1. 苏州大学附属第一医院呼吸与危重症医学科，苏州 215000
- Keywords:
Non-small cell lung cancer;
Dual immunotherapy;
Immune checkpoint inhibitors
- From:
Clinical Medicine of China
2024;40(3):232-236
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, with the wide application of immune checkpoint inhibitors, the landscape of non small cell lung cancer has changed dramatically. Immune checkpoints like programmed death protein/ligand 1(PD-1/PD-L1), cytotoxic T lymphocyte associated antigen-4(CTLA-4) are negative regulators of T-cell immune response. Inhibition of these immune checkpoints can further activate the immune system and promote anti-tumor response. Compared to the limited efficacy of monotherapy, reasonable dual immunotherapy shows great benefit at different stages of anti-tumour immunity. This article aims to comprehensively review the mechanism, treatment regimen and the latest clinical progress of dual immunotherapy so as to provide more precise and individualised immunotherapy for NSCLC patients.
